| Literature DB >> 34465633 |
Julian Braun1,2, Larissa Henze1,2, Beate Kruse1,2, Manuela Dingeldey1,2, Ulf Reimer3, Florian Kern3,4, Tatjana Schwarz5, Lucie Loyal1,2, Maike Mangold1,2, Clara Unger1,2, Friederike Dörfler1, Shirin Kadler1,6, Jennifer Rosowski1,6, Kübrah Gürcan1,6, Zehra Uyar-Aydin1,6, Marco Frentsch7,8, Florian Kurth9,10, Karsten Schnatbaum3, Maren Eckey3, Stefan Hippenstiel9, Andreas Hocke9, Marcel A Müller2,5,11, Birgit Sawitzki12, Stefan Miltenyi13, Friedemann Paul14,15, Marcus A Mall16,17, Holger Wenschuh3, Sebastian Voigt18,19, Christian Drosten2,5,11, Roland Lauster1,6, Nils Lachman20, Leif-Erik Sander9, Victor M Corman2,5,11, Jobst Röhmel16, Lil Meyer-Arndt1,2,14,15,21, Andreas Thiel1,2, Claudia Giesecke-Thiel22.
Abstract
The functional relevance of preexisting cross-immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a subject of intense debate. Here, we show that human endemic coronavirus (HCoV)–reactive and SARS-CoV-2–cross-reactive CD4+ T cells are ubiquitous but decrease with age. We identified a universal immunodominant coronavirus-specific spike peptide (S816-830) and demonstrate that preexisting spike- and S816-830–reactive T cells were recruited into immune responses to SARS-CoV-2 infection and their frequency correlated with anti–SARS-CoV-2-S1-IgG antibodies. Spike–cross-reactive T cells were also activated after primary BNT162b2 COVID-19 messenger RNA vaccination and displayed kinetics similar to those of secondary immune responses. Our results highlight the functional contribution of preexisting spike–cross-reactive T cells in SARS-CoV-2 infection and vaccination. Cross-reactive immunity may account for the unexpectedly rapid induction of immunity after primary SARS-CoV-2 immunization and the high rate of asymptomatic or mild COVID-19 disease courses.Entities:
Mesh：
Substances：
Year: 2021 PMID： 34465633 DOI： 10.1126/science.abh1823
Source DB: PubMed Journal: Science ISSN： 0036-8075 Impact factor: 47.728